Objective To identify genetic determinants of inflammatory bowel disease (IBD), we examined an association between polymorphisms of both the programmed cell death 1 gene (PDCD1) and the src homology 2 domain-containing tyrosine phosphatase 2 gene (PTPN11) and susceptibility to IBD. Methods Study subjects comprised 114 patients with ulcerative colitis (UC), 83 patients with Crohn's disease, and 200 healthy control subjects. Five single nucleotide polymorphisms (SNPs) in PDCD1 and PTPN11 were detected by polymerase chain reaction restriction fragment length polymorphism. Subsequently, haplotypes composed of the two SNPs in PTPN11 were constructed. Results The frequencies of the Hap 1 haplotype and its homozygous Hap 1/Hap 1 diplotype of PTPN11 were significantly increased in UC patients compared to control subjects (P=0.011 and P=0.030, respectively). While no association was found for PDCD1 for UC or CD and none for PTPN11 for CD. Conclusion PTPN11 is a genetic determinant for the pathogenesis of UC, and haplotyping of PTPN11 may be useful as a genetic biomarker to identify high-risk individuals susceptible to UC.
Introduction
Chronic inflammatory bowel disease (IBD) is a multifactorial disorder characterized by inflammation specific to the gastrointestinal tract, resulting in intestinal malabsorption, immune system abnormalities, and an exaggerated T-cell response [1] [2] [3] . IBD consists of two main subtypes: ulcerative colitis (UC) and Crohn's disease (CD) . Although the precise etiology of IBD remains unknown, several environmental factors, such as dietary components and microorganisms, and genetic factors may contribute to the occurrence of IBD [1] [2] [3] . Some genome-wide linkage analyses and candidate gene-based association studies with single nucleotide polymorphisms (SNPs), which focus on determining unknown genetic factors underlying the genetic determinants of the pathogenesis of IBD, have identified possible IBD-susceptibility genes and chromosomal loci [4] [5] [6] .
role in the pathogenesis of IBD. We have already found an association between a lack of susceptibility to UC in the Japanese population and a polymorphism of the cytotoxic T-lymphocyte antigen 4 gene (CTLA4) [10] , which expresses only on activated T cells as an immunoreceptor. During antigenic stimulation of T cells, CTLA4 downregulates T-cell activation after binding to B7-1 (CD80) and B7-2 (CD86) [11] [12] [13] [14] . As another immunoreceptor of the CD28/CTLA4 family, programmed cell death 1 (PD-1) is also expressed on T cells, as well as B cells and myeloid cells. PD-1 negatively signals T-cell activation and tolerance through the interaction of its specific ligands, PD-L1 or PD-L2 [13] [14] [15] . Moreover, polymorphisms of the PD-1 gene (PDCD1) are associated with susceptibility to autoimmune diseases, including systemic lupus erythematosus [16] [17] [18] , rheumatoid arthritis [19, 20] , and multiple sclerosis [21] in the Caucasian and Chinese populations.
Conversely, the inhibitory signals of both CTLA4 and PD-1 are mediated, at least in part, by the interaction with src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2), which plays a key role in the intracellular signaling elicited by a number of growth factors, hormones, and cytokines during development and hematopoiesis [15, [22] [23] [24] [25] . In addition, germline mutations of PTPN11 encoding SHP-2 cause Noonan and Leopard syndromes [26] [27] [28] , as well as somatic mutations in acute myeloid leukemia [29] . Moreover, an intronic polymorphism of PTPN11, but not exonic mutations, is associated with gastric atrophy in Japanese subjects infected with cagA-positive Helicobacter pylori [30] .
Despite the importance of the regulatory functions of PD-1 and SHP-2, no systemic studies have been reported on the association of genetic polymorphisms of PDCD1 and PTPN11 with IBD in the Japanese population or in other populations. Therefore, we investigated whether SNPs and their combination polymorphisms, referred to as haplotypes, in PDCD1 and PTPN11 are associated with IBD susceptibility in the Japanese population and whether SNPs can be used as new genetic biomarkers for predicting the onset of IBD.
Subjects and Methods

Subjects
The study subjects were all Japanese and unrelated, consisting of 114 patients with UC, 83 patients with CD, and 200 gender-matched, healthy volunteers as control subjects. The characteristics of the subjects are shown in Table I . IBD patients were enrolled from eight general health clinics in Nagasaki, Japan. The study protocol was approved by the Committee for Ethical Issues dealing with the Human Genome and Gene Analysis at Nagasaki University, and written informed consent was obtained from each subject.
The diagnosis of IBD was made on the basis of endoscopic, radiological, histological, and clinical criteria of both the World Health Organization Council for International Organizations of Medical Sciences and the International Organization for the Study of Inflammatory Bowel Disease [31, 32] . Patients with indeterminate colitis, multiple sclerosis, systemic lupus erythematosus, or other diagnosed autoimmune diseases were excluded from the study.
Preparation of Genomic DNA Genomic DNA was extracted from whole blood obtained from each subject using a DNA Extractor WB-Rapid Kit (Wako, Osaka, Japan) according to the manufacturer's protocol [10] .
Source of the Genes and their Polymorphisms
Three SNPs, nucleotide (nt) −538 G>A SNP (G-538A) in the promoter region, nt +7146 G>A SNP (G7146A) in intron 4, and nt +7785 C>T SNP (C7785T) in exon 5, in PDCD1 (GenBank accession no. NT_077995), located at 2q37.3, have been previously reported [17, 19, 21] . The adenine residue in the nucleotide sequence with respect to the transcriptional initiation site of this gene was numbered consecutively from +1. Two SNPs, rs2301756 in intron 3 and rs3741983 in intron 13, in PTPN11 (GenBank accession no. NT_009775), located at 12q24.13, were selected using data available in the JSNP database (http://snp.ims.u-tokyo.ac. jp/) and the International HapMap database (http://www. hapmap.org/). The rs2301756 SNP in the International HapMap database is identical with JST057927 G-to-A in the JSNP database [30] . The structures and positions of these SNPs sites in PDCD1 and PTPN11 are shown in Fig. 1 .
Determination of Three SNPs in PDCD1
The three SNPs, G-538A, G7146A, and C7785T, in PDCD1 were determined by polymerase chain reaction (PCR) restriction fragment length polymorphism. The polymorphic region was amplified by PCR with a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) using 20 ng of genomic DNA in a 25-µl reaction mixture containing 20 mM TrisHCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl 2 , 200 µM dNTPs, 15 pmol each of forward primer, 5′-GTGTGA GGCCATCCACAAG-3′, and reverse primer, 5′-ACCCC ACTCCCATTCTGTC-3′ for G-538A; forward primer, 5′-GCAGAGGTGGAAGGACAGG-3′, and reverse primer, 5′-AGGCAGGCACACACATGG-3′ for G7146A; forward primer, 5′-AGACGGAGTATGCCACCATTGTC-3′, and reverse primer, 5′-AAATGCGCTGACCCGGGCTCAT-3′ for C7785T, and 1 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). The amplification protocol consisted of initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing for 30 s at 60°C for G-538A, 63°C for G7146A, and 62°C for C7785T, and extension at 72°C for 30 s, and final extension at 72°C for 5 min. The PCR products were digested with MspI (New England BioLabs Inc., Beverly, MA, USA) for G-538A, PstI (Invitrogen) for G7146A, and PvuII (Takara Bio Inc., Kyoto, Japan) for C7785T. These digestion products were separated on a 6% polyacrylamide gel electrophoresis (Nacalai Tesque, Kyoto, Japan) and visualized with a UV transilluminator (Alpha Innotech Co., San Leandro, CA, USA) after ethidium bromide (Nacalai Tesque) staining.
Determination of Two SNPs in PTPN11
The two SNPs, rs2301756 and rs3741983, in PTPN11 were also analyzed by the same method. The polymorphic region was amplified by PCR using 15 pmol each of forward primer, 5′-CTGGTCTTGAACTCCTGGC-3′, and reverse primer, 5′-GACTTGCCGTCATTGCTCTC-3′ for rs230 1756; forward primer, 5′-GGTGCCAGAGTCTTTTC CAG-3′, and reverse primer, 5′-GCTCTGATCTCCAC TCGTC-3′ for rs3741983. The other constituents of the PCR mixture and the amplification protocol were the same as described above except with the annealing temperature at 60°C for rs2301756 and 62°C for rs3741983. The PCR products were digested with BanII (Toyobo, Osaka, Japan) for rs2301756 and MnlI (Fermentas International Inc., Ontario, Canada) for rs3741983. The digestion products were then separated by electrophoresis on a 2% agarose gel and visualized as described above.
Haplotype Structure of PTPN11 Subsequently, the two SNPs in PTPN11 were used for inference of the haplotype structure and for frequency analysis using SNP Alyze 7.0 standard (Dynacom Inc., Yokohama, Japan) to emphasize the variability and to enhance the power of detecting allelic association of rare variants.
Statistical Analysis
Differences in age and gender between patients and control subjects were evaluated by an unpaired Student's t test and a chi-square test, respectively, using SPSS 15 (SPSS Japan Inc., Tokyo, Japan) and Prism 4 (GraphPad Software Inc., San Diego, CA, USA). The frequencies of the expected alleles were calculated from those of the observed genotypes according to the Hardy-Weinberg equilibrium. The frequencies of observed and expected alleles were compared by a chi-square test with Yates' correction using SNP Alyze 7.0 standard. The frequencies and distributions of alleles, genotypes, haplotypes, and diplotypes were compared between patients and control subjects by the chi-square test and logistic regression analysis using SPSS 15 and Prism 4. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using SPSS 15. A P value of less than 0.05 was considered statistically significant.
Results
Association of SNPs in PDCD1 with Susceptibility to IBD
The frequencies and distributions of alleles and genotypes at the three SNP sites in PDCD1 were identified and compared between UC or CD patients and control subjects (Tables II and III, respectively) . G alleles at nt −538 and nt +7146 and the C allele at nt +7785 are major alleles, whereas the other alleles are minor alleles. The distributions of these SNPs in PDCD1 among IBD patients as well as control subjects corresponded well to the Hardy-Weinberg equilibrium, implying that our subject base has homogeneous genetic backgrounds. With respect to G7146A SNP, the A allele was not observed in the present study (Table II) , supporting previous results to show that this allele has been identified in the Caucasian and Africandescent populations but not in the Japanese population [33] . Furthermore, there were no significant differences in the frequencies of alleles and genotypes at the three SNP sites in PDCD1 between UC or CD patients and control subjects (Tables II and III) .
Association of SNPs in PTPN11 with Susceptibility to IBD
The frequencies and distributions of alleles and genotypes at the two SNP sites in PTPN11 were identified and compared between UC or CD patients and control subjects (Tables II and III, respectively) . The G allele at rs2301756 SNP and the T allele at rs3741983 SNP are major alleles, whereas the other alleles are minor alleles. The distributions of these SNPs in PTPN11 among IBD patients as well as control subjects corresponded well to the Hardy-Weinberg equilibrium. A chi-square test revealed that the frequencies of the G allele at rs2301756 and the T allele at rs3741983 were significantly increased in patients with UC as compared with those in control subjects (84.6% vs. 75.2%; P=0.008 and 83.3% vs. 75.7%; P=0.034, respectively; Table II ).
In addition, logistic regression analysis indicated that the frequencies of the G/G homozygous genotype at rs2301756 SNP and the T/T homozygous genotype at rs3741983 SNP were also significantly increased in patients with UC as compared with those in control subjects (71.1% vs. 57.5%; P=0.018, OR=1.814, 95% CI=1.109-2.968 and 68.4% vs. 56.0%; P=0.031, OR=1.702, 95% CI=1.050-2.761, respectively; Table III ). These results of the genotype analyses regarding PTPN11 polymorphisms coincided well with those of the allele analyses between UC patients and control subjects.
Association of Haplotypes and Diplotypes of PTPN11 with Susceptibility to IBD
Since a significant association was observed between allele and genotype polymorphisms at rs2301756 and rs3741983 SNPs in PTPN11 and susceptibility to UC, four haplotypes composed of these two SNPs were constructed and identified using SNP Alyze 7.0 standard (Table IV) . Logistic regression analyses revealed that the frequency of a haplotype, Hap 1 (G allele at rs2301756 and T allele at Each haplotype was compared with other haplotypes combined by logistic regression analysis rs3741983), was significantly increased in patients with UC as compared with that in control subjects (82.9% vs. 74.0%, P=0.011, OR=1.703, 95% CI=1.129-2.568; Table IV) . Whereas the frequency of another haplotype, Hap 2 (A allele at rs2301756 and C allele at rs3741983), was significantly decreased in UC patients as compared with that in control subjects (14.9% vs. 23.0%, P=0.016, OR= 0.587, 95% CI=0.381-0.904) (Table IV) . Furthermore, ten diplotypes composed of four haplotypes were identified (Table V) . Logistic regression analysis showed that the frequency of the UC patients possessing a Hap 1/Hap 1 diplotype was significantly higher than that of control subjects (67.5% vs. 55.0%, P=0.030, OR=1.703, 95% CI=1.053-2.754; Table V ). However, a Hap 2/Hap 2 diplotype showed no statistically significant lack of susceptibility to UC (Table V) . These results of the diplotype analysis regarding the Hap 1 haplotype of PTPN11 coincided well with those of the haplotype analysis between UC patients and control subjects.
Discussion
The present study is the first report to demonstrate an association between PTPN11 polymorphisms and susceptibility to UC in the Japanese population. The presence of the G allele and its homozygous G/G genotype at rs2301756 SNP, the T allele and its homozygous T/T genotype at rs3741983 SNP, the Hap 1 haplotype, and its homozygous Hap 1/Hap 1 diplotype in PTPN11 conferred susceptibility to UC. Inversely, the Hap 2 haplotype showed the statistically significant lack of susceptibility to UC. These findings imply that PTPN11 is a genetic determinant for predisposition to the onset of UC in Japanese individuals.
However, the current study population was relatively small, and further study on a larger number of the Japanese population and on other ethnic populations is necessary to confirm the association between PTPN11 and UC.
SHP-2, coded by PTPN11, is a key downstream molecule that downregulates T-and B-cell activation through interaction with CTLA4 and PD-1 [13] [14] [15] [22] [23] [24] [25] . SHP-2 is recruited to the phosphorylated tyrosine residue in the immunoreceptor tyrosine-based switch motif of the cytoplasmic tail of PD-1 and in the immunoreceptor tyrosine-based inhibitory motif of the cytoplasmic tail of CTLA4 [13-15, 34, 35] . Although the mechanisms of the PTPN11 polymorphisms identified in this study are unknown, PTPN11 polymorphisms may affect the expression, affinity to immunoreceptors, and inhibitory activities of SHP-2, leading to the reduction in the SHP-2 downregulatory effect on T-and B-cell activation.
Another mechanism of inflammatory suppression is the downregulation of SHP-2 on the interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway through binding of SHP-2 to the receptor complex, glycoprotein 130 and IL-6 receptor alpha [36, 37] . An increase in serum IL-6 concentrations and hyperactivation of STAT3 signaling have been reported in patients with IBD and experimental colitis in vivo [38] [39] [40] . Although the IL-6/STAT3 signaling is implicated in the pathogenesis of IBD, IL-6 expression and polymorphisms are associated with the progression and severity of IBD but not the onset [40] [41] [42] . These pathophysiological and genetic finings of IBD imply that the vicious pathway of T-cell activation driven by IL-6/STAT3 signaling can contribute to the perpetuation of chronic intestinal inflammatory process, probably resulting in the development of IBD. Thus, the reduction in the SHP-2 downregulatory effect against IL-6/STAT3 signaling due to its genetic polymorphisms may explain the progressing mechanism of IL-6-induced STAT3 hyperactivation in IBD patients. Germline mutations of PTPN11 have been reported in patients with the autosomal dominant-inherited Noonan and Leopard syndromes [26] [27] [28] , as well as somatic mutations in leukemogenesis [29] . These mutations are exclusively heterozygous missense mutations in exons containing the interacting portions of the amino terminal src homology 2 and protein tyrosine phosphatase domains, which introduce amino acid substitutions, leading to the gain-of-function of SHP-2 [43, 44] . On the other hand, an intronic polymorphism (rs2301756 SNP in intron 3 of PTPN11), but not an exonic mutation, is associated with gastric atrophy in Japanese individuals infected with cagA-positive H. pylori [30] , indicating persistent chronic inflammation in epithelial cells of the stomach in the individuals possessing the G/ A genotype at the rs2301756 SNP site in PTPN11. Atrophy of the gastric mucosae is the endpoint of chronic diseases and is often found in patients with chronic gastritis with H. pylori infection. Likewise, since persistent chronic inflammation in epithelial cells of the colon contributes to the pathogenesis of UC, chronic inflammation due to PTPN11 polymorphisms in the gastric and colon mucosae may be explained by the same mechanism. Thus, from the pathophysiological perspective, we speculate that intronic polymorphisms, especially possessing the Hap 1 haplotype and its homozygous Hap 1/Hap 1 diplotype, may interfere with gene expression. This causes a reduction of SHP-2 messenger RNA and protein levels, subsequently leading to the loss-of-function of SHP-2, which is in contrast to the gain-of-function of SHP-2 caused by exonic missense mutations of PTPN11. Therefore, the accumulation of altering the loss-of-function of SHP-2 caused by PTPN11 polymorphisms may lead to the reduction in the inhibitory effects against T-and B-cell activation, resulting in persistent chronic intestinal inflammation and the onset of UC.
Conclusions
As PTPN11 is a genetic determinant for susceptibility to UC in the Japanese population, intronic polymorphisms of PTPN11 may be useful as new DNA-based biomarkers for identifying individuals at high-risk for UC. Moreover, SHP-2 may be a good target molecule for novel drugs discovery.
